A multi-center retrospective study of Japanese patients, newly published in PLOS One, sought to describe treatment persistence and reasons for discontinuation among patients who were treating their rheumatoid arthritis with 1 of 7 biologic agents: adalimumab, etanercept, infliximab, golimumab, certolizumab pegol, tocilizumab, and abatacept.
Randomized controlled trials of drugs that treat rheumatoid arthritis (RA) are sometimes limited to patients who differ from those treated in the real-world setting, which has led to observational studies of cohort-based registries being increasingly used to investigate the performance of biologic disease-modifying anti-rheumatic drugs (DMARDs) in treating RA. A multi-center retrospective study of Japanese patients, newly published in PLOS One, sought to describe treatment persistence and reasons for discontinuation among patients who were treating their RA with 1 of 7 biologic agents: adalimumab, etanercept, infliximab, golimumab, certolizumab pegol, tocilizumab, and abatacept.
The study investigated the Kansai Consortium for Well-Being of Rheumatic Disease Patients (ANSWER) cohort, which, from 2011 to 2016, identified 750 patients—who had 1037 treatment courses—who were being treated with 1 of the 7 agents of interest.
Reasons for treatment discontinuation of the 7 biologics were classified into 4 main categories: inefficacy, remission, toxic adverse events (AEs), and nontoxic reasons (such as patient preference or pregnancy).
Overall, 455 (43.9%) of all treatment courses were stopped by month 36:
Drug retention rates, using an adjusted Kaplan-Meier estimate, were as follows at month 36:
Positive effects on treatment persistence were observed for concomitant methotrexate (hazard ratio [HR], 0.96; 95% CI, 0.94-0.98, P = .0002) or concomitant tacrolimus (HR, 0.63; 95% CI, 0.41-0.97, P = .036) treatment at baseline.
Negative effects on persistence were demonstrated with combined prednisolone treatment (HR, 1.02; 95% CI, 1.01-1.04, P = .0038), female sex (HR, 1.33; 95% CI, 1.06-1.69, P = .016), and number of previously administered biologics to treat RA (HR, 1.13; 95% CI, 1.04-1.22, P = .0031) at baseline.
At month 36, in adjusted models, drug retention rates due to inefficacy, toxic AEs, and remission, respectively, were as follows:
Overall, say the authors, abatacept and tocilizumab showed higher retention rates, tocilizumab showed lower inefficacy rates, and abatacept showed lower rates of toxic events compared to infliximab, but infliximab showed higher discontinuation rates to remission than abatacept, etanercept, golimumab, and tocilizumab after adjusting for potential confounders.
Reference
Ebina K, Hashimoto M, Yamamoto W, et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis—the ANSWER cohort study. PLOS One. 2018;13(3):e0194130. doi: 10.1371/journal.pone.0194130.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.